BioCity Biopharma announced that its endothelin receptor type A selective antagonist, SC0062, has successfully met the primary endpoint of proteinuria reduction in the 2-SUCCEED trial. This randomized, double-blind, placebo-controlled, dose-ranging phase 2 clinical trial evaluated the efficacy and safety of SC0062 in patients with chronic kidney disease (CKD).
The positive results from the 2-SUCCEED trial demonstrate the potential of SC0062 as a novel therapeutic option for patients with CKD, particularly those with IgA nephropathy. By selectively targeting the endothelin receptor type A, SC0062 has shown promise in reducing proteinuria, a key marker of kidney damage and progression in CKD.
BioCity Biopharma remains committed to advancing the development of SC0062 and bringing innovative treatments to patients with CKD. The company plans to present the detailed findings from the 2-SUCCEED trial at upcoming medical conferences and publish the results in a peer-reviewed journal.
